EDAP trades 110.3% below Wall Street's consensus target of $10.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes EDAP achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Edap Tms S.a. (EDAP) has a Wall Street consensus price target of $10.00, based on estimates from 8 covering analysts. With the stock currently trading at $4.75, this represents a potential upside of +110.3%. The company has a market capitalization of $178M.
Analyst price targets range from a low of $10.00 to a high of $10.00, representing a 0% spread in expectations. The median target of $10.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, EDAP trades at a trailing P/E of -6.1x. Analysts expect EPS to grow +4.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
AEYEAudioEye, Inc. | $79M | $6.31 | — | — | — | — | — |
ISRGIntuitive Surgical, Inc. | $144.5B | $406.78 | $597.78 | +47.0% | Buy | 38.9x | 55 |
NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
IRTCiRhythm Technologies, Inc. | $3.4B | $104.65 | $188.75 | +80.4% | Buy | — | 20 |
GKOSGlaukos Corporation | $7.6B | $130.68 | $151.25 | +15.7% | Buy | — | 24 |
VISTVista Energy, S.A.B. de C.V. | $7.1B | $68.55 | $85.33 | +24.5% | Buy | 6.1x | 6 |
PCVXVaxcyte, Inc. | $7.4B | $51.44 | $89.00 | +73.0% | Buy | — | 11 |
MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
BSXBoston Scientific Corporation | $67.3B | $45.29 | $82.90 | +83.0% | Buy | 13.5x | 44 |
SYKStryker Corporation | $117.9B | $307.80 | $387.46 | +25.9% | Buy | 20.5x | 51 |
Quick answers to the most common questions about buying EDAP stock.
The consensus Wall Street price target for EDAP is $10, representing 110.3% upside from the current price of $4.755. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
EDAP has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $10 implies 110.3% upside from current levels.
EDAP's current price is $4.755 with a consensus target of $10 (110.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $10 for EDAP, while the most conservative target is $10. The consensus of $10 represents the median expectation. These targets typically reflect 12-month expectations.
EDAP is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EDAP stock forecast based on 8 Wall Street analysts shows a consensus price target of $10, with estimates ranging from $10 (bear case) to $10 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on EDAP, with a "Buy" consensus rating and $10 price target (110.3% upside). 5 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EDAP analyst price targets range from $10 to $10, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.